Navidea Biopharmaceuticals Inc Quick Ratio (NAVB) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Navidea Biopharmaceuticals Inc   (NAVB)

Navidea Biopharmaceuticals Inc 's Quick Ratio

NAVB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 0.48 below Navidea Biopharmaceuticals Inc 's average Quick Ratio.

Within In Vitro & In Vivo Diagnostic Substances industry 13 other companies have achieved higher Quick Ratio than Navidea Biopharmaceuticals Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 1800 to 2724.

Explain Quick Ratio?
How much Cash & cash equivalents NAVB´s has?
What are NAVB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NAVB Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change -5.39 % 56.07 % 88.77 % 87.23 % 105.86 %
Y / Y Cash & cash equivalent Change -16 % 1773.06 % -97.22 % -52.83 % -35.89 %
Quick Ratio MRQ 0.48 0.74 0 0.2 0.55
NAVB's Total Ranking # 2724 # 1800 # 5240 # 3572 # 2559
Seq. Current Liabilities Change -3.94 % -10.21 % -6.78 % 17.67 % 58.45 %
Seq. Cash & cash equivalent Change -37.09 % 18079.82 % -98.31 % -56.62 % 1302.63 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 14
Healthcare Sector # 878
Overall Market # 2724


Quick Ratio Statistics
High Average Low
22.72 1.69 0
(Dec 31 2011)   (Mar 31 2023)




Financial Statements
Navidea Biopharmaceuticals Inc 's Current Liabilities $ 8 Millions Visit NAVB's Balance sheet
Navidea Biopharmaceuticals Inc 's Cash & cash equivalent $ 4 Millions Visit NAVB's Balance sheet
Source of NAVB's Sales Visit NAVB's Sales by Geography


Cumulative Navidea Biopharmaceuticals Inc 's Quick Ratio

NAVB's Quick Ratio for the trailling 12 Months

NAVB Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 48.02 % 83.05 % 79.73 % 62.56 % 40.95 %
Y / Y Cash & cash equivalent TTM Growth 16.01 % -1.37 % -64.75 % -68.72 % -57.59 %
Quick Ratio TTM 0.34 0.36 0.21 0.28 0.43
Total Ranking TTM # 4016 # 3793 # 4043 # 2708 # 2112
Seq. Current Liabilities TTM Growth -1.27 % 9.06 % 15.22 % 19.3 % 22.1 %
Seq. Cash & cash equivalent TTM Growth -5.76 % 83.58 % -14.53 % -21.54 % -19.88 %

Quick ratio ranking by company, industry and sector >> Back to NAVB Financial Strength Comparisons >> Go to Compare NAVB Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in NAVB's Current Liabilities to $7.98 millions, cumulative Quick Ratio to 0.34 below the NAVB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 15 other companies have achieved higher Quick Ratio than Navidea Biopharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3793 to 4016.

Explain Quick Ratio?
How much Cash & cash equivalents NAVB´s has?
What are NAVB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 16
Healthcare Sector # 1080
Within the Market # 4016


trailing twelve months Quick Ratio Statistics
High Average Low
1.48 0.67 0.05
(Dec 31 2021)   (Dec 31 2016)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within In Vitro & In Vivo Diagnostic Substances Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Cardio Diagnostics Holdings Inc   1.31 $ 3.630  Millions$ 2.777  Millions
Aspira Women s Health inc   1.04 $ 5.100  Millions$ 4.926  Millions
Volitionrx Limited  0.61 $ 10.809  Millions$ 17.654  Millions
Immucell Corporation  0.60 $ 1.989  Millions$ 3.328  Millions
Navidea Biopharmaceuticals Inc   0.48 $ 3.865  Millions$ 7.979  Millions
Myriad Genetics Inc   0.41 $ 86.300  Millions$ 209.300  Millions
Trinity Biotech Plc  0.35 $ 5.207  Millions$ 15.035  Millions
Idexx Laboratories Inc  0.34 $ 331.696  Millions$ 970.193  Millions
Quidelortho Corp  0.22 $ 193.200  Millions$ 860.000  Millions
Burzynski Research Institute Inc  0.22 $ 0.001  Millions$ 0.006  Millions

Date modified: 2026-08-29T17:28:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.